Abstract：
BACKGROUND: Lupus nephritis affects 40 to 70% of Systemic Lupus Erythematous(SLE) patients increasing their morbi-mortality; therefore, successful treatments are required to improve outcomes.
UNASSIGNED: In this paper 20 patients who participated in the BLISS LN trial at a single center (OMI) in Argentina were studied. All the patients continued Mycophenolate (MMF) treatment when the trial was finished and until a second biopsy was performed to determine the withdrawal of the immunosuppression according to the achieved clinical and histological response. Ten patients treated with MMF + Placebo versus 10 receiving MMF + Belimumab, were compared evaluating the complete clinical (CCR) and complete histological response (CHR) and the flares in each group.
RESULTS: All the patients in the Belimumab group showed a CCR and 7 in the Placebo one; CHR was found in 9 and 5 patients of the Belimumab and Placebo group, respectively. None of the patients in the Belimumab group flared meanwhile two of the Placebo one did it.
CONCLUSIONS: Although the number of patients is insufficient to be able to draw unquestionable conclusions, adding Belimumab to the standard of care treatment with MMF would seem to increase the possibility of achieving a CCR, CHR, and a lower rate of relapses during treatment and long follow-up.
UNASSIGNED: In this paper 20 patients who participated in the BLISS LN trial at a single center (OMI) in Argentina were studied. All the patients continued Mycophenolate (MMF) treatment when the trial was finished and until a second biopsy was performed to determine the withdrawal of the immunosuppression according to the achieved clinical and histological response. Ten patients treated with MMF + Placebo versus 10 receiving MMF + Belimumab, were compared evaluating the complete clinical (CCR) and complete histological response (CHR) and the flares in each group.
RESULTS: All the patients in the Belimumab group showed a CCR and 7 in the Placebo one; CHR was found in 9 and 5 patients of the Belimumab and Placebo group, respectively. None of the patients in the Belimumab group flared meanwhile two of the Placebo one did it.
CONCLUSIONS: Although the number of patients is insufficient to be able to draw unquestionable conclusions, adding Belimumab to the standard of care treatment with MMF would seem to increase the possibility of achieving a CCR, CHR, and a lower rate of relapses during treatment and long follow-up.
摘要：
背景：狼疮性肾炎影响40％至70％的系统性红斑狼疮（SLE）患者，增加其死亡率；因此，需要成功的治疗来改善预后.研究设计和研究样本：本文研究了阿根廷单中心（OMI）参与BLISSLN试验的20名患者。试验结束后，所有患者均继续霉酚酸酯（MMF）治疗，直到进行第二次活检，以根据所达到的临床和组织学反应确定免疫抑制的退出。10例接受MMF+安慰剂治疗的患者与10例接受MMF+Belimumab治疗的患者相比，比较评估各组的完整临床（CCR）和完整组织学反应（CHR）以及耀斑。结果：Belimumab组中的所有患者在安慰剂组中显示CCR和7；在Belimumab和安慰剂组中的9和5例患者中发现了CHR，分别。Belimumab组中没有一个患者在安慰剂组中的两个患者中发作。结论：尽管患者人数不足以得出不容置疑的结论，将Belimumab添加到MMF的护理治疗标准中似乎会增加实现CCR的可能性，CHR,治疗和长期随访期间复发率较低。
